Sarcoma: Page 2

Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
2020 04 14 22 00 7772 Business Men Handshake 400
BLOODPAC to host virtual liquid biopsy summit
The summit aims to provide an update on the state of liquid biopsy science, as well as outline strategic objectives for the future.
March 29, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Guardant wins new clearances in Japan for liquid biopsy test
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
2022 03 08 19 56 8772 Clearance Stamp 400
Insightec to launch new trials of Exablate Neuro
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
2022 03 10 18 19 1134 Mri Head 400
Invitae launches 2 IVD cancer tests in Europe
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
2022 01 12 21 29 6223 Europe Signpost 400
PierianDx, Biodesix partner on lung cancer diagnostics
PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).
January 18, 2022
2019 09 05 21 14 7857 Heart Pulmonary Trunk 400
Lucence offers expanded cfRNA version LiquidHallmark
Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."
January 9, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
Personalis releases liquid biopsy for molecular residual disease
The test is sensitive to molecular residual disease to the 1 ppm range, which represents a tenfold to hundredfold improvement over other tests, according to the firm. The assay can identify up to 1,800 somatic variants that can be used to create a personalized liquid biopsy panel for each patient.
December 15, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Quest offers Biocept's liquid biopsy test
Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.
December 1, 2021
2019 05 13 16 12 9218 Lab Blood Woman2 400
Lucence, Yemaachi team up on liquid biopsy study in Africa
The trial, called The Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer (AMBER), will prospectively explore the utility of Lucence's LiquidHallmark cell-free DNA (cfDNA) liquid biopsy assay in identifying actionable genetic mutations in metastatic breast cancer patients in Ghana.
October 25, 2021
2019 07 27 00 04 3609 Breast Cancer Cell 400
Guardant initiates study of its liquid biopsy test
The observational multicenter study -- Observation of Residual Cancer With Liquid Biopsy Evaluation (ORACLE) -- will enroll 1,000 patients. The study will analyze circulating tumor DNA (ctDNA) levels from blood samples of patients with early-stage cancer using the Guardant Reveal test after the end of treatment and during routine follow-up.
October 4, 2021
2020 10 19 22 00 1118 Blood Cells 400
Liquid biopsy may detect ALK fusions in lung cancer patients
Liquid biopsy also could be used to serially monitor the development of mechanisms of resistance in response to targeted therapy.
July 27, 2021
2019 09 09 20 46 2283 Lung Cancer 400
Previous Page
Page 2 of 5
Next Page